US Patent Issued to Memorial Sloan Kettering Cancer Center on Dec. 30 for "CD22 antibodies and methods of using the same" (New York Inventors)

ALEXANDRIA, Va., Dec. 31 -- United States Patent no. 12,509,515, issued on Dec. 30, was assigned to Memorial Sloan Kettering Cancer Center (New York).

"CD22 antibodies and methods of using the same" was invented by Nai-Kong V. Cheung (New York), Sayed Shahabuddin Hoseini (New York) and Mahiuddin Ahmed (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CD22 protein. The antibodies of the present technology are useful in methods for detecting and treating a CD22-associated cancer, a CD22-associated autoimmune disease, or a CD22-associated allergy in ...